Dordaviprone targets mitochondrial protease and dopamine receptor D2, representing a novel approach in cancer therapy for H3 K27M-mutant diffuse glioma. The drug application seeks accelerated FDA ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

DUBLIN, Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso ™ ...

A Corbin family is receiving an outpouring of community support after their young daughter, Millee Kate Daugherty, was diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG), a rare and ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

What Is Modeyso, and Why Does It Matter? Modeyso (dordaviprone) is a new oral medicine that treats a rare and aggressive brain tumor, called diffuse midline glioma (DMG), that has a tumor mutation ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...

Genomic newborn screening for cancer risk: A retrospective cohort study. Cognitive outcomes following proton vs. photon radiotherapy for CNS non-germinomatous germ cell tumors: A Children’s Oncology ...

Pediatric low-grade gliomas (pLGGs) exhibit distinct biological and clinical characteristics compared to adult gliomas, and their treatment strategies differ substantially from those used in adults.

Dordaviprone has been granted Priority Review by the FDA for recurrent H3 K27M-mutant diffuse glioma, with a target action date of August 18. The drug has received Rare Pediatric Disease, Fast-Track, ...